Clinical Characteristics, Treatment Patterns, and Outcomes of Patients With Locally Advanced/Metastatic Hepatocellular Carcinoma Treated at the Veterans Health Administration
The Oncologist · 2024
DOI: 10.1093/oncolo/oyad343 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2024. Verfasst von Munaf A Alkadimi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Long School of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Purpose
This study retrospectively reviewed the outcomes of patients with advanced hepatocellular carcinoma (HCC) receiving atezolizumab with bevacizumab (A + B) therapy at the Veterans Health Administration (VHA). Patients and Methods Patients with advanced HCC who received first-line systemic therapy with A + B at the VHA between December 1, 2019, and March 1, 2022, were selected from electronic medical records (EMR) using ICD-9 and ICD-10 codes. Abstractors reviewed the EMR of the patients from their index date of A + B initiation until death or their last VHA visit, with the study period ending on January 31, 2023. The chi-square test was used to compare rates, and the Mann-Whitney test was used to compare medians.
Results
A total of 332 patients met the study criteria. The median age was 67 years; 99% were male, 63% were non-Hispanic Whites, 26% were Black, and 66% had an Eastern Cooperative Oncology Group performance status of ≥1. 84% had child Pugh score (CPS) class A, 16% had CPS classes B and C, 62% had a grade 2 albumin-bilirubin score, 56% had HCC caused by viral hepatitis, 80% had cirrhosis, and 67% had received prior local therapies. The 6-month progression-free survival (PFS) was 59%, while the 1-year PFS rate was 36%. Overall survival (OS) at 1-year was 52% in our study.
Conclusion
In real world, despite having similar PFS as the phase III IMbrave 150 trial, our OS at 12 months was lower (52% vs. 67%) because our study included a higher proportion of elderly patients with moderate liver dysfunction and a 40% non-White. This study provided real-world outcomes that differed from the study population in a pivotal trial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Long School of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.
- South Texas Veterans Health Care System, San Antonio, TX, USA.
ORCID-Profile: Munaf A Alkadimi, Zohra Nooruddin
Zitieren
APA
Alkadimi, M. A., Aldawoodi, T. A., Lucero, K. T., Fierro, M. E., Boyle, L. D., Mader, M. J., Franklin, K. R., Arora, S. P., & Nooruddin, Z. (2024). Clinical Characteristics, Treatment Patterns, and Outcomes of Patients With Locally Advanced/Metastatic Hepatocellular Carcinoma Treated at the Veterans Health Administration. The Oncologist. https://doi.org/10.1093/oncolo/oyad343
Vancouver
Alkadimi MA, Aldawoodi TA, Lucero KT, Fierro ME, Boyle LD, Mader MJ, et al. Clinical Characteristics, Treatment Patterns, and Outcomes of Patients With Locally Advanced/Metastatic Hepatocellular Carcinoma Treated at the Veterans Health Administration. The Oncologist. 2024. doi:10.1093/oncolo/oyad343
BibTeX
@article{Alkadimi2024,
author = {Alkadimi, Munaf A and Aldawoodi, Tamarah A and Lucero, Kana T and Fierro, Maria E and Boyle, Lauren D and Mader, Michael J and Franklin, Kathleen R and Arora, Sukeshi P and Nooruddin, Zohra},
title = {Clinical Characteristics, Treatment Patterns, and Outcomes of Patients With Locally Advanced/Metastatic Hepatocellular Carcinoma Treated at the Veterans Health Administration},
journal = {The Oncologist},
year = {2024},
doi = {10.1093/oncolo/oyad343}
}
EUVIMED